AstraZeneca delivers its largest shipment of over two million COVID-19 vaccine doses to Malaysia

A further 2,017,500 doses of COVID-19 Vaccine AstraZeneca (ChAdOx1-S [Recombinant]) were delivered to Malaysia today in support of the country's booster vaccination programme. Today’s delivery is in addition to 324,000 doses delivered last week, bringing this month’s total supply to over 2.3 million doses.

The latest shipment is part of AstraZeneca’s bilateral commitment to deliver 6.4 million doses directly to Malaysia. To date, over 7.8 million doses of AstraZeneca’s vaccine have been delivered to Malaysia through direct supply, COVAX, and donations from other countries. The final shipment of vaccine doses under the bilateral commitment is expected next month.

Dr Sanjeev Panchal, Country President, AstraZeneca Malaysia, said: “Today’s delivery is our largest shipment to Malaysia to-date, ramping up efforts to ensure the availability of vaccine doses to support booster roll-out. With the emergence of Omicron, we will continue to partner with the government to support the boosting of Malaysians as quickly as possible.”

More than 2.5 billion doses of AstraZeneca’s vaccine have been released for supply to over 170 countries. Approximately two-thirds of doses have gone to low- and lower-middle-income countries.

COVID-19 Vaccine AstraZeneca
COVID-19 Vaccine AstraZeneca, (ChAdOx1-S [Recombinant]), formerly AZD1222, was invented by the University of Oxford. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

The vaccine has been granted a conditional marketing authorisation or emergency use in more than 90 countries. It also has Emergency Use Listing from the World Health Organization, which accelerates the pathway to access in up to 144 countries through the COVAX Facility.

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit and follow the Company on Twitter @AstraZeneca

For further details, please contact

Approval code: MY_AZ_MY-8347_21/01/2022